New Journey(SZ:002219)2025-10-31 01:06Revenue Performance - Medical services segment achieved revenue of 2.018 billion CNY, a year-on-year decrease of 13.88% due to adjustments in medical insurance payment policies [2] - Pharmaceutical segment reported revenue of 238 million CNY, down 60.46% year-on-year, primarily impacted by centralized procurement of the "Duyiwai" series products [2] Cost Management - Sales expenses decreased by 35% year-on-year, mainly due to reduced sales expenses in the pharmaceutical segment following price drops from centralized procurement [3] - Management expenses fell by 23% year-on-year through strict budget management and performance reforms [3] - Drug cost ratio was 36%, down 4 percentage points year-on-year, while effective revenue ratio increased by 3 percentage points [3] Operational Adjustments - Bed occupancy rate was nearly 80%, slightly down year-on-year, as the company adjusted patient admission strategies in response to ongoing medical insurance payment reforms [6] - Plans to add over 2,000 beds, representing a 30% increase, with new facilities under construction [6] Future Outlook - The company aims to stabilize and improve pharmaceutical segment performance through refined sales strategies and market coverage [7] - Anticipates significant recovery in performance starting from September, driven by proactive measures and strategic investments [8] - Focus on enhancing "health technology" positioning and exploring innovative business segments for future growth [8]